Clinical Trial Halt Raises Questions over Nusantara Vaccine’s Progress

By Editorial Team 20/04/2021
COVID-19 vaccine vials
Summary

The Ministry of Health, the Food and Drug Monitoring Agency (BPOM), and the Indonesian National Armed Forces (TNI) agreed to suspend clinical trials for the Nusantara Vaccine. A source told Katadata that Health Minister Budi Gunadi Sadikin, Army Chief of Staff General Andika Perkasa, and the Head of BPOM Penny Kusumastuti Lukito agreed on a meeting Monday (4/19) to suspend the trial.

According to the source, Penny, Andika, and Budi agreed that the dendritic cell research used in the Nusantara vaccine development could continue. However, the research is not for commercial purposes, so there is no need for a distribution permit and not for mass vaccination. "It would be treated as a private-purpose research instead of the follow-up of the clinical trials," said the source. The Nusantara Vaccine research would be continued at the Gatot Soebroto Central Army Hospital (RSPAD), Central Jakarta.

Register now and get free access.

If you want to get free access to our Daily Insights and Weekly Digest, please click "Sign up" button below. If you already have an account, please login.

Sign up
Log in
What do subscribers receive?

As a subscriber, you'll receive daily insights, weekly business digests, and quarterly industrial reports.

What kind of pieces will i get?

In-depth reports on assumption and impact analysis, as well as update and trends mapping, written by our credible and experienced analysts.

And, there is something else…

Register now and get free access, click here to register. Feel free to contact us with any additional questions you have.